Antidiabetics Market by Product and Application - Global Industry Analysis and Forecast to 2025

Report Code : HC0651

Diabetes is a chronic disease in which the pancreas is not able to produce enough insulin or when the body cannot use the insulin effectively. Insulin is the hormone responsible for the glucose absorption into the cells. The symptoms of diabetes are unusual thirst, frequent urination, increased hunger, blurred vision, tingling sensation, and rapid weight loss. Diabetes if not treated on time can cause complications such as heart attack, stroke, kidney failure, leg amputation, vision loss, nerve damage, foot ulcers, and damage to the eyes or even death. There are three types of diabetes, namely, type 1, type 2, and gestational diabetes. In type 1 diabetes, the body cannot produce enough insulin; whereas in type 2, body cannot use the produced insulin. Gestational diabetes is a form of high blood sugar that affects pregnant women. This form of diabetes is also known as diabetes during pregnancy. The risk factors for diabetes are physical inactiveness, depression, high blood pressure, obesity, and family history of diabetes.

Antidiabetic drugs are used for controlling diabetes. These medicines help to control and stabilize the blood glucose level. In patients with type 1 diabetes, insulin is used, whereas in patients with type 2 diabetes, sulfonylureas, biguanides, meglitinides, dipeptidyl-peptidase-4 (DPP-4) inhibitors, alpha-glucosidase inhibitors, sodium glucose cotransporter 2 inhibitors (SGLT2), and glucagon-like peptide-1 (GLP-1) agonist are used.  In type 1 diabetes, the insulin used is created by growing insulin proteins within E-coli bacteria in laboratory. The analog insulin is available into various forms. One of the forms is long acting analog insulin. The long acting analog insulin stays in the body for 18 to 24 hours, whereas the intermediate acting analog insulin stays in the body for 18 to 24 hours. Another form of insulin is rapid acting analog insulin. Rapid acting analog’s onset of action is 15 minutes. On the other hand, short acting analog stays in the body for 6 to 8 hours. Further, premixed analog insulin is also a form of insulin which is used in diabetes. It is made by combining rapid acting and long acting insulin in a ratio. However, in type 2 diabetes patients, sulfonylureas are used. Sulfonylureas stimulate the insulin production in the pancreas. Moreover, sulfonylureas help in increasing the amount of insulin which is produced by the pancreas. Thiazolidinediones is another class of antidiabetic drugs. Thiazolidinediones reduce insulin resistance in fat and muscles. They also lower glucose production by the liver. Meglitinide is another class of antidiabetic drug. Amount of insulin produced by pancreas is increased with the help of meglitinides. Moreover, GLP-I agonists help in maintenance of blood sugar in a target range without leading to low blood sugar or weight gain, whereas alpha glucosidase inhibitors slow down the digestion of starch thus maintaining the blood sugar level.

The major drivers for this market are increasing incidence of diabetes. According to IDF, in 2015, diabetes affected 415 million people worldwide and this number is expected to reach up to 642 million by 2040. Moreover, it was found that one in 11 adults was suffering from diabetes. Thus, this rapidly rising diabetic population is set to drive the demand for antidiabetic medicines. Another factor for antidiabetic market growth is increasing trend of unhealthy diet. Moreover, increased prevalence of obesity is also an important factor that will fuel the market growth. Obesity occurs due to excessive fat accumulation which risks the health of an individual. It also occurs due to physical inactivity and sedentary lifestyle. For instance, according to WHO, in 2014, more than 1.9 billion people aged 18 years and older were overweight. Out of these, over 600 million were obese. Moreover, it states that, in 2014, 41 million children whose age was under 5 were obese or overweight. In addition, the rise in prevalence of geriatric population will further contribute to the market growth. For instance, according to WHO, in 2015, 900 million people were 60 years of age or older and the number is expected to reach up to 2 billion by 2050. On the other hand, reduction in the drug efficiency over a period will hamper the growth of antidiabetic market.

Manufacturers are highly focused on introducing generics related to diabetes as most of the product patents are set to expire in near future. This will bring in ample growth opportunities for the generic drug manufacturers. For instance in November 2015, Zydus Cadila launched Tenglyn which is a generic drug. Tenglyn contains Teneligliptin which belongs to a new class of oral anti-diabetic drugs known as Gliptins. This drug achieves glycemic control without deteriorating beta cell. This helped the company to make the therapy affordable to diabetic patients.

The key strategy followed by the major players is product launch to increase their share, expand product portfolio and gain competitive advantage in the market. For instance, in July 2016, Sanofi-Synthelabo (India) Private Limited launched ZEMIGLO in India. ZEMIGLO contains Gemigliptin. It comes under the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class of anti-diabetic drugs. This class is also known as gliptins. This product launch enabled Sanofi to expand its portfolio which will help gain more market share.

The key players in the antidiabetics market are Boehringer Ingelheim International GmbH, Oramed Pharmaceuticals, Inc., Sanofi, Pfizer Inc., Eli Lilly and Company, Takeda Pharmaceuticals Limited, Merck & Co., Inc., and Bristol-Myers Squibb.

Antidiabetic Market Segmentation:

By Product:

  • Insulin
    • Long Acting Analog
    • Premixed Insulin
    • Intermediate Acting Insulin
    • Premixed Analog
    • Rapid Acting Analog
    • Short Acting Analog
  • Other Antidiabetics
  • Sulfonylureas
  • Biguanides
  • Thiazolidinedione
  • Meglitinides
  • GLP-I (Glucagon like Peptide) Agonists
  • SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
  • Alpha-Glucosidase Inhibitors
  • DPP-IV (Dipeptyl Peptides) Inhibitors

By Type:

  • Type I Diabetes
  • Type II Diabetes
  • Gestational Diabetes

By Region:

  • North America
  • U.S
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • Rest of the World
  • Brazil
  • South Africa
  • Saudi Arabia
  • Turkey
  • United Arab Emirates
  • Others

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers


Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Further Assistance